Apricot Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Apricot Capital.
Key people at Apricot Capital.
Key people at Apricot Capital.
Apricot Capital is a leading investment firm founded in 2015 and based in Shanghai, China, with a specialized focus on the healthcare sector, particularly biotech, medtech, and life sciences. Its mission is to nurture groundbreaking innovation and bridge China’s burgeoning biotech ecosystem with the global healthcare landscape. The firm invests primarily in early- and growth-stage companies that address critical unmet clinical needs worldwide, covering areas such as gene therapy, cell therapy, nucleic acid drugs, medical devices, diagnostics, and biotech supporting services like CROs and AI-driven drug discovery. Apricot Capital has built a portfolio with over 70 companies and has transacted more than $12 billion in value, positioning itself as a top 20 healthcare venture capital firm in 2024[1][2].
Apricot Capital was established in 2015 by founding partners Dr. Crystal Liu and Arthur Qiang. The leadership team combines strong academic credentials from prestigious institutions such as Johns Hopkins, Harvard, and Tsinghua University with practical experience in clinical medicine, pharmaceutical analysis, healthcare operations, and entrepreneurship. This blend of scientific insight and financial expertise has shaped the firm’s evolution from a general venture investor to a specialized healthcare-focused firm deeply embedded in China’s life sciences ecosystem. The firm’s growth reflects a strategic focus on incubating and scaling innovative biotech and medtech companies that can compete on a global stage[1].
Apricot Capital rides the global trend of rapid innovation in biotechnology and healthcare, particularly the convergence of advanced therapies (gene and cell therapy), digital health, and AI applications in drug discovery. The timing is critical as China emerges as a major player in life sciences, supported by government initiatives and increasing global collaboration. Apricot Capital’s role is pivotal in bridging Chinese innovation with global markets, accelerating the commercialization of novel therapies and technologies that address significant unmet medical needs. This positions the firm as a key influencer in shaping the future of healthcare innovation both regionally and globally[1].
Looking ahead, Apricot Capital is likely to deepen its investment footprint in transformative biotech and medtech sectors, leveraging its strong scientific and operational expertise to back category-defining companies. Trends such as personalized medicine, AI-driven drug development, and global biotech collaboration will shape its journey. The firm’s influence is expected to grow as it continues to bridge China’s healthcare innovation with international markets, fostering a more integrated global biotech ecosystem. This trajectory aligns with its mission of driving innovation for life and creating lasting impact in healthcare[1].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Zhiran Medical | $43.4M Series A | CAS Star | Baidu Ventures, Beijing Medical and Health Industry Investment Fund, BioVenture, IDG Capital, Jiayin Capital, Legend Capital, Lenovo Capital and Incubator Group (LCIG), Longzhu Capital, Sequoia Capital, Shunwei Capital |
| Feb 2, 2026 | Microtide Biotechnology | Series A | — | Qiming Venture Partners, Xiamen C&D Corporation |
